Galecto (Galecto) Cash-to-Debt : 175.30 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Galecto Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Galecto's cash to debt ratio for the quarter that ended in Mar. 2024 was 175.30.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Galecto could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Galecto's Cash-to-Debt or its related term are showing as below:

GLTO' s Cash-to-Debt Range Over the Past 10 Years
Min: 37.9 Med: 102 Max: No Debt
Current: 175.3

During the past 6 years, Galecto's highest Cash to Debt Ratio was No Debt. The lowest was 37.90. And the median was 102.00.

GLTO's Cash-to-Debt is ranked better than
81.94% of 1539 companies
in the Biotechnology industry
Industry Median: 6.49 vs GLTO: 175.30

Galecto Cash-to-Debt Historical Data

The historical data trend for Galecto's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Galecto Cash-to-Debt Chart

Galecto Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

37.90

178.78

118.29

74.91

133.14

Galecto Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															77.62	83.27	95.21	133.14	175.30

Competitive Comparison of Galecto's Cash-to-Debt

For the Biotechnology subindustry, Galecto's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galecto's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galecto's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Galecto's Cash-to-Debt falls into.

Galecto Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Galecto's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	33.151	/	(0.183	+	0.066)
	=	133.14

Galecto's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	27.171	/	(0.155	+	0)
	=	175.30

Galecto (NAS:GLTO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Galecto Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Galecto's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Galecto (Galecto) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galecto Inc (NAS:GLTO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.galecto.com

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis-related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bertil Lindmark	officer: Chief Medical Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Hans T. Schambye	director, officer: Chief Executive Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Stephanie Oestreich	officer: Chief Business Officer	75 STATE STREET, SUITE 100, BOSTON MA 02109
Jonathan Freve	officer: Chief Financial Officer	C/O SPRING BANK PHARMACEUTICALS, INC., 113 CEDAR STREET, STE S-7, MILFORD MA 01757
Garrett Winslow	officer: General Counsel	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Anne Prener	director	C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
Dallas Jayson Donald Alexander	director	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Chau Quang Khuong	director, 10 percent owner	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Stephan Christgau	director	C/O CASTLE & MORGAN HOLDINGS, INC., 425 MARKET STREET, SUITE 2230, SAN FRANCISCO CA 94105
Soren Moller	director	C/O NOVO HOLDINGS A/S, TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Anders Pedersen	officer: Chief Operating Officer	C/O GALECTO, INC., OLE MAALOES VEJ 3, COPENHAGEN N G7 DK-2200
Orbimed Advisors Israel Ii Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Gp Ii, L.p.	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022